Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XUBJA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Her3-ADC-07 (DAR8)
|
|||||
| Synonyms |
Her3 ADC 07 (DAR8)
Click to Show/Hide
|
|||||
| Organization |
Suzhou Medilink Therapeutics Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Colon cancer [ICD11:2B90]
Investigative
Lung cancer [ICD11:2C25]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
7.98
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-Her3 mAb 202-2-1
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-3 (ERBB3)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Her3-ADC-07(DAR8) linker
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% (Day 18) | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | SW480 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW480 cells | CVCL_0546 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 61.50% (Day 18) | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | SW480 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW480 cells | CVCL_0546 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 70.20% (Day 15) | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | SW480 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW480 cells | CVCL_0546 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 76.26% (Day 29) | Low CD276 expression (CD276 +) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | NCI-H358 CDX model | ||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 85.60% (Day 29) | Low CD276 expression (CD276 +) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 5 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | NCI-H358 CDX model | ||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 93.20% (Day 18) | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | SW480 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW480 cells | CVCL_0546 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 94.40% (Day 15) | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | SW480 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW480 cells | CVCL_0546 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 49.26 nM | Positive HER3 expression (HER3 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
|
||||
| In Vitro Model | Lung adenocarcinoma | PC-9 cells | CVCL_B260 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 183.30 nM | Positive HER3 expression (HER3 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.